{"url_path":"/sec/apls/8-k/2026-05-14/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","accession_number":"0001193125-26-222923","cik":"0001492422","ticker":"APLS","issuer_name":"Apellis Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","primary_entity_key":"0001492422","primary_entity_name":"Apellis Pharmaceuticals, Inc."},"word_count":180,"has_tables":true,"body_markdown":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\nOn May 13, 2026, the Company (i) notified The Nasdaq Stock Market (“Nasdaq”) of the anticipated consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective at 8:00 p.m., Eastern Time, on May 13, 2026, and, following the Effective Time, (y) file with the U.S. Securities and Exchange Commission (the “SEC”) a Form 25, Notification of Removal from Listing and/or Registration, to delist and deregister the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15, requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.\n\nThe information set forth in the Introductory Note and Item 5.01 of this Current Report on Form 8-K is incorporated herein by reference."}